In the field of urological oncology there can be no greater therapeutic challenge for the urologist and radiotherapist than a bladder tumour which is found to be infiltrating muscle. The threat to life by such lesions is of varying magnitude, depending upon the precise depth of mural infiltration. In patients with tumour limited to the superficial muscle (stage T2), cure is anticipated, whereas in those cases showing involvement of deep muscle or perivesical fat (stage T3a and T3b), therapeutic failure leading to death within two years is not unexpected.
In the field of urological oncology there can be no greater therapeutic challenge for the urologist and radiotherapist than a bladder tumour which is found to be infiltrating muscle. The threat to life by such lesions is of varying magnitude, depending upon the precise depth of mural infiltration. In patients with tumour limited to the superficial muscle (stage T2), cure is anticipated, whereas in those cases showing involvement of deep muscle or perivesical fat (stage T3a and T3b), therapeutic failure leading to death within two years is not unexpected.
Bladder tumours with muscle involvement are not early enough to be dismissed after one or more sessions of transurethral cystodiathermy, nor so late as to be relegated to palliative procedures. A radical approach is required, although in some cases not necessarily amounting to total cystectomy nor to large volume external beam therapy. T2 tumours Before the megavoltage era, interstitial irradiation was an attractive method of treatment, enabling high doses to be delivered locally in a deep-seated organ without heavily irradiating the normal surrounding tissues. With the advent of megavoltage equipment and with more aggressive methods of endoscopic resection, the indications for interstitial treatment for bladder cancer have diminished. Thus, at the Christie Hospital, Manchester, the proportion of cases treated by radioactive implant has fallen from 41% in 1953 in , to 3% in 1969 in (Pointon 1973 .
Interstitial irradiation in the bladder now appears to be used at only a few centres, mainly in Europe. The techniques and materials for this type of treatment have been reviewed elsewhere (Bloom & Wallace 1971) .
The ideal case for interstitial therapy is one with a solitary tumour of relatively low-grade malignancy whose base does not exceed 4-5 cm in diameter, with early muscle infiltration and with no obvious malignant or premalignant changes in the bladder away from the tumour site. This technique has also been employed for patients with mucosal tumours (T1) which are large, sessile and solid-looking, and especially when biopsy shows poor differentiation and there is doubt regarding the precise depth of infiltration.
The principal advantages associated with interstitial irradiation are that a substantial cure rate is obtained with a low operative morbidity and mortality (2-4%); that irradiation is restricted to a portion of the bladder wall, with sparing of the extravesical tissues; and that if cure is not achieved, other methods of treatment are not precluded. The disadvantages of the technique are that an open operation is required, and that treatment is restricted to the primary tumour and is suitable only for tumours of limited size and penetration. The staff, both medical and paramedical, are exposed to irradiation, but with the usual precautions this should be within acceptable levels.
Overall 5-year results for interstitial irradiation range between 50% and 60% (Poole-Wilson 1957 , Riches 1958 , Carver 1959 , Bloom 1960 , Dix et al. 1970 ), but these figures are largely governed by the proportion of cases presenting with and without muscle infiltration. In the past, bladder tumours were often classified as 'mucosal', 'submucosal', 'muscular' or 'perivesical', depending upon the depth of infiltration, with no distinction made between superficial and deep muscle involvement. Several authors have reported results for interstitial irradiation according to this grouping: the 5-year crude survival rate was generally about 70% for patients with mucosal and submucosal lesions, and approximately 40% for those with muscle involvement, mostly superficial but some deep (Poole-Wilson 1957 , Bloom 1960 , Munro 1964 . In a recent report, Werf-Messing (1978) presented radio-implant results strictly according to the modern TNM classification of the UICC. The crude 5-year survival rates for T2 and T3 cases using radium needles alone were 56% and 10% respectively. Clearly, interstitial irradiation alone is totally inadequate for T3 tumours, but the results for T2 lesions are particularly encouraging.
In a series of retrospectively re-staged patients treated by interstitial irradiation (using radiogold grains or radio-tantalum wire) at the Royal Marsden Hospital and St Peter's Group of Hospitals, the net 5-year survival rate ranged between 81 % and 20% according to surgical stage (Table 1) . One may suspect that most TI and perhaps some T2 tumours, treated in the past by interstitial irradiation, could have been just as effectively eradicated by transurethral diathermy. However, interstitial irradiation reduces local recurrence and may improve survival, compared with transurethral diathermy, particularly in patients with the less welldifferentiated tumours (Riches 1958) , especially if early muscle infiltration is present. Miller et al. (1969) have demonstrated only too well the inadequacy of transurethral diathermy alone for undifferentiated bladder tumours; no less than 37% of such patients died with tumour extension within 5 years, compared with less than 2% of patients with differentiated tumours treated by the same method. It is difficult to compare results of radio-implants with those of diathermy alone because of the undoubted selection of less favourable cases for the interstitial treatment.
Local treatment, such as interstitial irradiation, does not seem adequate for T3 tumours, nor for many T2 tumours, bearing in mind such factors as wide circumferential, intramural lymphatic spread (Baker 1968 ) and involvement of perivesical and pelvic lymph nodes (Jewett et al. 1964) , which are often associated with these tumours. Nevertheless, experience has shown that, providing a tumour is solitary, of limited size and moderately well-differentiated, with infiltration no deeper than superficial muscle, a less radical approach using interstitial irradiation is often successful: it is particularly suitable for elderly patients (Table 2 ). An alternative and equally successful procedure for T2 tumours situated towards the bladder dome is partial cystectomy. A gross 5-year survival rate of 40-50% can be achieved following either of these treatments.
More radical approaches to the control of T2 tumours have not produced consistently better results. Following megavoltage irradiation 5-year survival rates of between 26% and 40% have been reported by Caldwell et al. (1967) , Miller & Johnson (1973 ), Goffinet et al. (1975 and Edsmyr (1975) . Cystectomy alone or combined with preoperative irradiation (4000 rad in 4 weeks or 2000 rad in one week) has given 5-year survival rates of 45-53% (Cordonnier 1968 , Whitmore et al. 1977 , Werf-Messing 1975 .
Case selection, based on factors involving the tumour, such as size, site and grade, and the host, such as age and general condition, materially influence the choice of therapeutic procedure. Results will consequently be biased in particular treatment groups. Within a given stage, some indication of potential tumour malignancy and likelihood of regional lymphatic spread may be gained from the histological grade, and this may influence therapeutic approach. The 5-year survival rate for patients with T1 undifferentiated tumours was 60% following interstitial irradiation, compared with 41% for transurethral diathermy; the corresponding figures for T2 cases were 32% and 7% respectively (Bloom 1971) .
It is most important for treatment and prognosis to distinguish between T2 and T3 tumours. If a case is classified as T2 and a radioactive implant is recommended, it is not too late to withdraw from the local procedure and change to a more radical one if, at laparotomy, the tumour is found to be more advanced.
T3 tumours
Once the half-way mark of the bladder muscularis has been breached by tumour, the prognosis becomes extremely serious. For these lesions there is generally but one chance for curative treatment, which must be radical from the outset and undertaken without delay.
A few carefully selected small T3 tumours may appear to be suitable for local treatment such as segmental resection, in which case postoperative external beam therapy substantially increases the chance of cure (Bloom 1971) . Interstitial therapy in 45 cases with T3 tumours at the Royal Marsden Hospital produced a 3-year survival rate of 33%, but at 5 years only 18% were still alive. Werf-Messing (1978) reported a 5-year survival rate of only 10% for T3 cases treated by radium implant alone; but when this was combined with limited preoperative external beam therapy, there was a remarkable improvement in results, with 42% surviving 5 years.
With involvement of deep muscle in the bladder wall, nodal metastases are found in 40-50% of cases (Jewett & Strong 1946 , Kerr & Colby 1951 , Whitmore et al. 1977 . A few carefully selected small T3 tumours may appear suitable for local treatment, such as segmental resection or radio-implant. However, for treatment purposes, it would seem prudent to regard deeply invasive bladder cancer as a 'pelvic disease', for which whole pelvic irradiation or radical cystectomy with node dissection would appear to be more rational approaches to treatment than any procedure limited to part of the bladder wall or even to the whole bladder.
The 5-year survival rate for T3 cases following radical cystectomy alone does not exceed 20%. Similar results generally follow radical megavoltage irradiation, although some centres report slightly better rates, up to 28% (Table 3) . These results for external beam therapy represent a real challenge to radical surgery, since they can be achieved without hospitalization and without the operative mortality and morbidity, including the loss of urinary and sexual functions, associated with radical cystectomy. Bearing in mind the extent to which cases are selected for radical operation, the overall results of megavoltage irradiation may, in fact, be superior to those of surgery. The outlook for patients with T3 tumours depends on whether the lesion is confined to deep muscle or has further extended into the perivesical fat. Pomerance (1972) , at the Royal Marsden Hospital, reported a 5-year survival rate of 29% following cystectomy for P3a cases, compared with only 2% for those with P3b lesions. In any series, the relative incidence of these two categories will influence results materially and this may account for differences found in various reports. This also may explain the encouraging results achieved for some T3 cases by the limited treatment of interstitial irradiation or segmental resection, especially when combined with external beam therapy (Bloom 1971 , Werf-Messing 1978 . Cystectomy for radiotherapy failures Among patients with T3 tumours in whom radical megavoltage radiotherapy fails to control the disease (6000-7000 rad in 6 to 7 weeks), delayed cystectomy may save lives. The late tissue changes associated with such doses, however, make operation more difficult and the morbidity and mortality greater than after planned preoperative radiotherapy. Following late cystectomy in failed radiotherapy cases, Whitmore et al. (1977) reported a 5-year survival rate of almost 50% for T2 cases and 30% for T3 cases.
Operative mortalities of 16% and 20% have been reported for salvage cystectomy (Whitmore et al. 1977 , Miller & Johnson 1973 . These can undoubtedly be reduced by recognizing radiotherapy failures at an early stage and operating before the disease becomes too advanced or fibrosis well-established. In the Institute of Urology multicentre trial, 18 patients treated by radical radiotherapy were selected for salvage cystectomy because of residual or recurrent local tumour. The 5-year survival rate for this small group was 52%: the operative mortality was only 11% (2 of 18 cases) (Wallace & Bloom 1976 ). These results are surely a tribute to the surgical skill of the urologists participating in the trial.
Combined treatment
The presence of residual or re6urrent disease in the bladder and/or pelvis in at least 50% of patients with T3 tumours following radical radiotherapy, and the failure to achieve better survival rates with radical surgery, have led to the introduction of a combined treatment using sub-radical external beam therapy followed by radical cystectomy. The aim of preoperative irradiation is to reduce tumour bulk and tumour cell viability prior to surgery. Actively growing, well-oxygenated cells at the periphery of the tumour and micrometastases in regional nodes may be particularly vulnerable to this limited treatment. It is thereby hoped to increase the margin of resection and reduce the risk of tumour spill and dissemination at the time of cystectomy. Finally, radical cystectomy will remove residual, radio-resistant tumour at the primary site and in pelvic nodes.
In patients with T3 tumours, a combination of preoperative irradiation and radical cystectomy appears to give results superior to those of either modality alone. Five-year survival rates of 34-50% have been reported for T3 cases following the combined approach in noncontrolled studies at the Rotterdam Radiotherapy Institute (Werf-Messing 1975), the Memorial Hospital, New York (Whitmore et al. 1977 ) and the Montreal General Hospital (Reid et al. 1976) (Table 4) .
Recently the results were reported of a cooperative randomized trial involving eight London hospitals and organized by the Institute of Urology and the Royal Marsden Hospital (Wallace & Bloom 1976 ). The 5-year actuarial rate of 98 patients allocated to preoperative pelvic irradiation (4000 rad in 4 weeks) followed by radical cystectomy 4 weeks later was 33%, compared with 21% for 91 patients in the purely radical radiotherapy group (6000 rad in 6 weeks). A similar trend in results, also in a randomized study, has been reported by Miller & Johnson (1973) : 51% of patients receiving the combined treatment were alive at 5 years compared with 13% following radical radiotherapy alone ( Table 5) .
Effect of preoperative irradiation on primary tumour and nodal metastases
Substantial bladder tumour regression may occur following sub-radical, preoperative irradiation (4000 rad in 4 weeks). Down-staging is seen in 40-50% of T3 cases, and in about 30% 21% radiotherapy (1976) (6000 rad/6 weeks) no residual tumour is found in the subsequent surgical specimen. As expected, following lower doses of preoperative irradiation (2000 rad in 1 week) with immediate operation, the proportion of cases showing tumour regression is reduced (Table 6) .
Of special interest in the Institute of Urology trial was the apparent effect of 4000 rad on pelvic lymph node metastases. In only 23% (18/77) of the T3 cases were nodes involved, compared with an expected incidence of 40(50% in purely surgical cases. In those cases showing reduction in stage of the primary tumour following irradiation, the incidence of positive nodes was only 8%, compared with 37% for those showing no such improvement (Table 7) . This suggests that a good radiation response in the primary bladder tumour is associated with a good response of metastases in regional nodes. Until recently, the presence of node involvement in patients with bladder cancer treated by cystectomy was considered to indicate a hopeless prognosis. There is a high mortality in cases with positive lymphograms (Turner et al. 1976 ). However, this investigation reveals only gross disease and our therapeutic endeavours may not be entirely wasted in patients with nodal micrometastases. There is evidence that strictly limited node involvement is indeed compatible with survival for 5 or more years following radical surgery (Dretler et al. 1973 , Laplante & Brice 1973 .
In the Institute of Urology trial, the survival rate in down-staged (P0, PIS, P1, P2) cases (with positive nodes in 8%) following preoperative radiotherapy was more than twice as great as for those showing no such change (P3, P4) (with positive nodes in 37%): at 3 years, 66% were alive compared with 29%, and at 5 years, 510% compared with 22% (Table 7) . Following preoperative radiation and cystectomy in T3 cases survival rates of 50% were also reported for tumour-free cases (P0) by Prout et al. (1973) , and at 7 years for down-staged cases (P0, P1, P2) by Werf-Messing (1975) .
Operative mortality for combined treatment In the Institute of Urology study, the operative mortality within two months of radical cystectomy following preoperative radiotherapy was 8%. It varied from 5.5% for patients aged less than 60 years to 1 1% for those aged 65-70 (Wallace & Bloom 1976 ). In the series reported by Whitmore et al. (1977) the hospital mortality was 14% for radical cystectomy alone and 110% for operation after 4000 rad. It is clear that preoperative irradiation to doses of 4000 rad with operation 4 weeks later is not associated with a greater mortality than surgery alone.
Prognosis influenced by age
For patients under 65 years of age preoperative irradiation and radical surgery appear to be superior to radiotherapy alone. There was no advantage for the combined treatment in older people, for whom we now recommend radical radiotherapy alone with the possibility of delayed surgery in selected cases if the primary treatment fails (Wallace & B3loom 1976) .
Shorter preoperative radiation schedules
The overall time of combined therapy programmes for bladder cancer involving preoperative irradiation (4000 rad in 4 weeks) can be as long as 12 weeks (Bloom 1971) . From radiobiological considerations, doses of the order of 1000-2000 rad, or perhaps even a few hundred rad given over a few days immediately prior to surgery, may also be of value in reducing the risk of local and distant spread (Werf-Messing 1978) . This shorter type of treatment would have the great advantage of enabling patients to return to a normal life more quickly. On the other hand, with such brief treatment there is virtually no time to benefit from an increase in vascularity leading to reoxygenation and therefore greater responsiveness in the remaining tumour fraction for which, in more prolonged radiotherapy programmes, there is still treatment in hand. Nevertheless, limited preoperative irradiation does appear to be of value. Following a pelvic dose of only 350 rad x 3 prior to interstitial therapy in T3 cases, Werf-Messing (1978) reported a reduced incidence of scar recurrence and of distant metastases, with an increased 5-year survival rate, compared with radium implant alone. A dose of 2000 rad in one week prior to cystectomy in T3 cases has given results which are not inferior to those following a preoperative dose of 4000 rad in 4 weeks (Whitmore et al. 1977 , Reid et al. 1976 ) (Table 4 ).
Future studies
Since reduction of tumour stage and apparent clearance of pelvic nodes following preoperative radiotherapy in T3 cases is associated with improved survival rates for radical cystectomy, it would seem reasonable to pursue the principle of combined treatment and to aim for a greater incidence and degree of tumour regression prior to operation. This could perhaps be achieved with chemical radiosensitizers such as nitroimidazole and nitrofuran derivatives, which are at present under investigation in several centres, or by adjuvant chemotherapy. The latter may have the additional merit of being effective against micrometastases outside the irradiated volume. Carter & Wasserman (1975) found significant cytotoxic activity against bladder cancer with only three agents, namely adriamycin, 5-fluouracil and mitomycin-C. We have reported on the effect of methotrexate in advanced cases (Hall et al. 1974 , Turner et al. 1977 : the overall objective response rate in 61 patients treated with this agent was 38%, with remissions lasting two to six months (average 8.7 months). Intravenous doses of 50, 100 or 200 mg were given every two weeks, the greatest dose level being associated with a citrovorum rescue procedure.
The objective response rate in 38 patients receiving doses of either 100 or 200 mg was 53% (Table 8 ). In further pilot studies we found that neither adriamycin (25 mg/M2 i.v. every 3 weeks), nor bleomycin (5 mg/M2 i.m. twice weekly) were of benefit in patients with advanced bladder cancer. In studies elsewhere, cis-platinum appears to be of considerable promise in such cases and deserves further study (Yagoda 1977) . Our aim is to develop a combined chemotherapy programme which includes methotrexate for patients with deeply infiltrating tumours. Such treatment may be administered during two weeks prior to preoperative irradiation and then as maintenance therapy for 9-12 months following recovery from surgery.
The presence of metastases from pelvic cancers in the para-aortic nodes does not necessarily mean that blood-borne metastases have occurred (Vongtama et al. 1974) . Irradiation of the para-aortic nodes may therefore be of value in the combined treatment of patients with proven or suspected pelvic node involvement from bladder cancer, and in whom there may be limited para-aortic node disease. However, careful consideration would have to be given to dose-time factors, because of potential risk of heavy irradiation to gastrointestinal tissue (Piver & Barlow 1977) .
At the present time interstitial irradiation or segmental resection may be used for suitable, moderately differentiated T2 tumours. Preoperative irradiation and radical cystectomy is recommended for poorly differentiated T2 tumours and all T3 lesions, irrespective of grade. For patients over 65, radical radiotherapy is preferred, with radical cystectomy reserved for selected irradiation failures. In patients with pelvic node metastases, 'prophylactic' irradiation of the para-aortic nodes should be considered.
To achieve better results for infiltrating tumours we first need wider acceptance of the international system of clinical staging, since information in many reports is at present wasted because of inappropriate classifications and grouping of cases. We also need close cooperation between urologists, radiotherapists and chemotherapists, to explore the value of combined modality treatment in multicentre prospective controlled trials. The opportunity to increase further the survival of T3 cases following combined treatment may soon become available through the use of chemical radiosensitizers, which it is hoped will achieve a greater tumour response in the irradiated volume, and through the administration of cytotoxic agents which may destroy not only residual tumour in the irradiated volume, but also distant micrometastases.
Urology Group, Kings College Hospital, the London Hospital, Oldchurch Hospital and the Royal Marsden Hospital), who have participated in the Institute of Urology Bladder Trial, the preliminary results of which indicate possible means of achieving greater control of highly lethal deeply infiltrating tumours.
